Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The company’s full-year revenue guidance of $59.5 billion at the midpoint ...

Analysts expect Eli Lilly’s EPS to climb 107.9% to $13.14 in fiscal 2024, up from $6.32 in 2023.In fiscal 2025, EPS is projected to increase by 82.9% annually to $24.03.

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

In Q4 2024, Eli Lilly's revenue grew 45%, driven by Mounjaro and Zepbound, the company's core weight-loss drugs. Non-incretin revenue grew by 20% compared to Q4 2023. "We exceeded our first-time ...

Eli Lilly also posted a 90 bps improvement in gross margin to 83.2% in Q4. Higher revenues clubbed with margin expansion resulted in earnings of $5.32 per share, up over 2x from the $2.49 figure ...

Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year.

Eli Lilly Mounjaro Zepbound GLP-1 Lilly on Thursday reported fourth-quarter revenue of $13.53 billion, a steep 45% increase over the sum the Indianapolis-based drugmaker generated during the same ...

Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for further gains. Analysts see 27% upside.